Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Abemaciclib + LY3537982|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Abemaciclib||Verzenio||LY2835219||CDK4/6 Inhibitor 11||Verzenio (abemaciclib) is a dual CDK4/6 inhibitor, which inhibits Rb1 protein phosphorylation and may induce cell cycle arrest and prevent growth in cancer cells (PMID: 24919854). Verzenio (abemaciclib) is FDA approved as a monotherapy and in combination with Faslodex (fulvestrant) in patients with hormone receptor-positive (ESR, PGR) and ERBB2 (HER2) receptor-negative advanced or metastatic breast cancer, in combination with endocrine therapy as adjuvant treatment for patients with hormone receptor-positive (ESR, PGR) and ERBB2 (HER2) receptor-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score equals to or over 20% (FDA.gov).|
|LY3537982||LY 3537982|LY-3537982||KRAS G12C inhibitor 15||LY3537982 selectively inhibits KRAS G12C, potentially leading to growth inhibition of KRAS G12C-expressing tumor cells (Cancer Res 2021;81(13_Suppl):Abstract nr 1259).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04956640||Phase I||LY3214996 + LY3537982 LY3537982 + Sintilimab Erlotinib + LY3537982 Abemaciclib + LY3537982 LY3537982 Cetuximab + LY3537982 LY3295668 + LY3537982||Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)||Recruiting||USA||1|